Results 31 to 40 of about 25,109 (253)

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

Breast Cancer Research, 2018
Background Upregulation of human epidermal growth factor receptor 3 (HER3) is a major mechanism of acquired resistance to therapies targeting its heterodimerization partners epidermal growth factor receptor (EGFR) and human epidermal growth factor ...
Takuya Osada, Zachary C. Hartman, Junping Wei, Gangjun Lei, Amy C. Hobeika, William R. Gwin, Marcio A. Diniz, Neil Spector, Timothy M. Clay, Wei Chen, Michael A. Morse, H. Kim Lyerly   +11 more
doaj   +1 more source

Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology. [PDF]

PLoS ONE, 2013
Heteromerization can play an important role in regulating the activation and/or signal transduction of most forms of receptors, including receptor tyrosine kinases (RTKs).
Mohammed Akli Ayoub, Heng B See, Ruth M Seeber, Stephen P Armstrong, Kevin D G Pfleger   +4 more
doaj   +1 more source

HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells

npj Precision Oncology, 2023
Patients with triple-negative breast cancer (TNBC) have a poor prognosis and high relapse rate due to limited therapeutic options. This study was conducted to determine the mechanisms of action of panobinostat, a pan-inhibitor of histone deacetylase ...
H. Lyu, Defu Hou, Hao Liu, S. Ruan, Congcong Tan, Jiande Wu, C. Hicks, Bolin Liu   +7 more
semanticscholar   +1 more source

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7

Biochemistry and Biophysics Reports, 2018
HER3, a member of the receptor tyrosine kinase super family, is overexpressed in a number of cancers, and is associated with malignant phenotypes. Control of the protein stability of the membrane, as well as nuclear receptors, has been known to be an ...
Junko Suga, Keiko Izumiyama, Nobuyuki Tanaka, Shigehira Saji   +3 more
doaj   +1 more source

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

Talanta, 2014
The development of a new impedimetric biosensor for the detection of HER3, based on self-assembled monolayers (SAMs) of 4-aminothiophenol on gold electrodes, is reported. Anti-HER3 was used as a biorecognition element for the first time in an impedimetric biosensor.
Sonuc, Munteha Nur, Sezginturk, Mustafa Kemal   +1 more
openaire   +4 more sources

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models [PDF]

Clinical Cancer Research, 2017
Abstract Purpose: Our previous work suggested that HER3 inhibition sensitizes head and neck squamous cell carcinoma (HNSCC) to EGFR inhibition with cetuximab. This study aimed to define the role of HER3 in cetuximab resistance and the antitumor mechanisms of EGFR/HER3 dual targeting in HNSCC.
Dongsheng, Wang, Guoqing, Qian, Hongzheng, Zhang, Kelly R, Magliocca, Sreenivas, Nannapaneni, A R M Ruhul, Amin, Michael, Rossi, Mihir, Patel, Mark, El-Deiry, J Trad, Wadsworth, Zhengjia, Chen, Fadlo R, Khuri, Dong M, Shin, Nabil F, Saba, Zhuo G, Chen   +14 more
openaire   +2 more sources

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition

OncoImmunology, 2017
Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies.
Takuya Osada, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, Hongtao Guo, Xiao-Yi Yang, Cong-Xiao Liu, Kensuke Kaneko, Gloria Broadwater, H. Kim Lyerly   +12 more
doaj   +1 more source

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations [PDF]

Science Signaling, 2014
Cancer-associated mutations in the catalytically inactive receptor HER3 enhance its ability to activate other members of the human epidermal growth factor receptor family.
Littlefield, Peter, Liu, Lijun, Mysore, Venkatesh, Shan, Yibing, Shaw, David E, Jura, Natalia   +5 more
openaire   +4 more sources

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. [PDF]

PLoS ONE, 2018
INTRODUCTION:Expression of human epidermal growth factor receptor (HER)2 and HER3 have been investigated in small BTC studies using variable scoring systems.
Angela Lamarca, Salvatore Galdy, Jorge Barriuso, Sharzad Moghadam, Elizabeth Beckett, Jane Rogan, Alison Backen, Catherine Billington, Mairéad G McNamara, Richard A Hubner, Angela Cramer, Juan W Valle   +11 more
doaj   +1 more source

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

Biomedicines, 2022
Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HER3) could be a viable route for targeted cancer therapy. Here, we studied a novel drug conjugate, ZHER3-ABD-mcDM1, consisting of a HER3-targeting affibody
Sara S. Rinne, Wen Yin, Anna Mestre Borras, Ayman Abouzayed, Charles Dahlsson Leitao, Anzhelika Vorobyeva, John Löfblom, Stefan Ståhl, Anna Orlova, Torbjörn Gräslund   +9 more
doaj   +1 more source